Bayer: to make 11 presentations at the 31st ESGCT meeting

(CercleFinance.com) - Bayer subsidiary Asklepios BioPharmaceutical will make 11 presentations offering an overview of the research and development of adeno-associated virus (AAV) therapies for a range of diseases, as well as advances in manufacturing technologies, at the 31st annual meeting of the European Society of Gene and Cell Therapy (ESGCT), to be held October 22-25, 2024, in Rome, Italy.


Two oral presentations and nine poster presentations will highlight progress in AskBio's clinical and preclinical pipeline and advances in the company's manufacturing technologies.

' This year's presentations complement recent notable progress in our clinical pipeline, with the first patient randomized in our Phase 2 GenePHIT trial for AB-1002, an investigational gene therapy for congestive heart failure, and the start of enrollment for REGENERATE-PD, our Phase 2 Parkinson's disease trial for AB-1005 investigational gene therapy. said Gustavo Pesquin, CEO of AskBio.

Copyright (c) 2024 CercleFinance.com. All rights reserved.